CAR-T cell therapy for relapsed B-cell blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This early-stage trial tests a new type of immune cell therapy (LVIVO-TaVec122) designed to fight back against B-cell lymphomas and leukemias that have stopped responding to previous treatments. The goal is to see if this therapy is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that has come back after treatment or stopped responding to it
- You need to be at least 18 years old and in reasonably good overall health (able to carry out light activities)
- You must have at least one tumor that doctors can measure on imaging scans
- Your blood work and organ function must meet the study's safety standards
- You cannot have had certain prior treatments (like stem cell transplants or other gene therapies) without enough time passing first
- You cannot have hepatitis B, hepatitis C, or HIV, and cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses a virus to make your own immune cells attack two targets on cancer cells. It is for people with B-cell blood cancers that have come back or not responded to other treatments.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
This trial tests a personalized CAR-T cell treatment that targets a marker called CD79b in people whose B-blood cancers have come back or not responded to prior treatment. It may help your immune system find and attack cancer cells, but it also requires you to meet safety and health criteria.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.